July 14, 2016 6:55am

… While there is no perfect answer to questions on overbought timing

There is one thing that everyone needs, and that's sector intelligence borne from information collection and data analysis because …

... It’s a trading arcade and investing tends to be a bazaar event!

 

How to trade, I identify positions to make money with a 76% batting average

 

I offer a tool set of pertinent facts and targeted analysis defining the who, when, where, which and what of it!

Where is today’s market going – subscribe and find out! 

 

 

Where do investors turn for insight and perspective - I say intelligently what others won't, so you can do what others can't!

 

Companies in the headlights: BLFS, BLUE, CAPR and CLLS

Indexes and ETFs: The IBB (+0.78), XLV (+0.65%), IWM (+0.89%) and the XBI (+0.39%) are UP

Dow futures are UP +0.79% and NASDAQ futures are UP 0.73%

 

U.S. stock-index futures leaped on Thursday as equity markets around the world rallied, partly on the back of greater political stability in the U.K.

European stocks rallied after the U.K.'s new Prime Minister Theresa May took office and named her cabinet, bringing stability to the country's political scene post-Brexit, and as investors anticipate easier monetary policy from central banks globally.

Asian markets ended mostly higher, with major indexes extending their week-long rallies, while trading in Singapore's securities market was halted due to a system glitch.

Data docket: Q2 earnings and the latest weekly jobless claims. There will also be Producer Price Index (PPI) figures for June.

 

 

The stem, cell and gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Wednesday, POSITIVE on Tuesday, NEGATIVE on Monday, POSITIVE on Friday as well as last Thursday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Wednesday closed Wednesday with 29 decliners, 13 advancers and 1 flat;
  • Tuesday closed POSITIVE with 16 decliners, 24 advancers and 3 flats;
  • Monday closed NEGATIVE with 25 decliners, 16 advancers and 2 flats;
  • Friday closed POSITIVE with 13 decliners, 29 advancers and 1 flat;
  • Last, Thursday closed POSITIVE with 15 decliners, 24 advancers and 4 flats;

 

 

Remembering Wednesday’s post, “There are much fewer gains ahead because resistance is extremely fickle.”

  • Reflecting upon the title, intelligence is both a product and a process containing insufficiencies and inadequacies as does the market.

The purpose of my writing is to aid in formulating and implementing a program of trading – buy or sell, up or out.

  • Thus, I am a collector of information and inclined to “frost” the cake, which is also a matter of arrangement and decoration.

A lot of the talking heads are TOO indebted to their “handlers” but, lose sight of the means and ends of investors – pricing of the BUY or SELL.  

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Wednesday down -1.75% and is UP +0.78% in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Wednesday down -2.93% and is UP +0.39% in Thursday’s  pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down Wednesday -0.04% and UP +0.65% in Thursday’s pre-market;
  • The iShares Russell 2000 (IWM) closed Wednesday down -0.39% and is UP +0.89% in Thursday’s pre-market.

 

 

Companies in my spotlight:

BioLife Solutions (BLFS) closed UP +$0.18 to $2.25 after being down on Tuesday to $2.07 (-$0.30) after being UP +$0.80 On Monday after announcing a 10 year contract with KITE. I also believe that BLFS has more problems i.e. “a going concern issue”.  At the end of 3/31/16, BLFS had $1.66 M in cash and is spending $8.832 M per quarter <$1.379 M for R&D and $7.543 M in SG&A expenses> offset by a gross profit from revenue of $3.814 M. Yesterday, the market dictated a BUY, the aftermarket indication is DOWN -$0.06 - BUY to SELL;

Bluebird bio (BLUE) closed DOWN -$3.46 to $46.52. A glaring oversold based on what, another’s issue (JUNO and KITE). The aftermarket indication is UP +$0.46 or +0.99% - BUY;

Capricor (CAPR) closed UP +$0.0859 to $4.13. CAPR has been on a roll of low to moderate volume <4,298> with an upside post Tuesday’s $4.04 <7,900>, Monday’s $4.10 <8,400>following Friday’s $4.02 <15,600>. CAPR desperately needs to raise cash, Q2 results spending will defined  its “runway” and the ultimate question of whether Jansen (J&J) will execute on their collaboration option especially with issues on manufacturing of clinical material – Maintaining SELL;

Cellectis SA (CLLS) closed UP +$0.44 to $25.85. CLLS bounced down hard due to another’s issues (JUNO) as low as $25.15 on Friday.  The aftermarket is positive and UP +$0.58 or +2.23% - BUY

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.